Joseph J Grzymski
Overview
Explore the profile of Joseph J Grzymski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foley J, Kwiatkowski C, Rochester J, Neveux I, Dabe S, Lathrop M, et al.
Int J Environ Res Public Health
. 2025 Jan;
22(1).
PMID: 39857552
Background: Daily-use products, including personal care products, household products, and dietary supplements, often contain ingredients that raise concerns regarding harmful chemical exposure. Endocrine-disrupting chemicals (EDCs) found in daily-use products are...
2.
Read R, Schlauch K, Elhanan G, Neveux I, Koning S, Cooper T, et al.
Front Public Health
. 2024 Dec;
12:1447008.
PMID: 39697282
As complex mental health traits and life histories are often poorly captured in hospital systems, the utility of using the Barratt Impulsivity Scale (BIS) and Adverse Childhood Experiences (ACEs) for...
3.
Combining rare and common genetic variants improves population risk stratification for breast cancer
Bolze A, Kiser D, Schiabor Barrett K, Elhanan G, Schnell Blitstein J, Neveux I, et al.
Genet Med Open
. 2024 Dec;
2:101826.
PMID: 39669587
Purpose: This study aimed to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer in the general population. Methods: We retrospectively studied...
4.
Schiabor Barrett K, Telis N, McEwen L, Burrows E, Khuder B, Judge D, et al.
Commun Med (Lond)
. 2024 Nov;
4(1):239.
PMID: 39567669
Background: Natural HbA1c levels in GCK Maturity-onset diabetes of the young (GCK-MODY) patients often sit above the diagnostic threshold for type 2 diabetes (T2D). Treatments to lower HbA1c levels show...
5.
Kiser D, Elhanan G, Bolze A, Neveux I, Schlauch K, Metcalf W, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2435901.
PMID: 39320887
Importance: Most patients with pathogenic or likely pathogenic (P/LP) variants for breast cancer have not undergone genetic testing. Objective: To identify patients meeting family history criteria for genetic testing in...
6.
Rochester J, Kwiatkowski C, Neveux I, Dabe S, Hatcher K, Lathrop M, et al.
Int J Environ Res Public Health
. 2024 Jul;
21(7).
PMID: 39063482
Background: Interventions are needed to help people reduce exposure to harmful chemicals from everyday products and lifestyle habits. Report-back of individual exposures is a potential pathway to increasing environmental health...
7.
Marchal A, Cirulli E, Neveux I, Bellos E, Thwaites R, Schiabor Barrett K, et al.
HGG Adv
. 2024 Apr;
5(3):100300.
PMID: 38678364
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic...
8.
Cirulli E, Schiabor Barrett K, Bolze A, Judge D, Pawloski P, Grzymski J, et al.
HGG Adv
. 2024 Mar;
5(3):100284.
PMID: 38509709
Systematic determination of novel variant pathogenicity remains a major challenge, even when there is an established association between a gene and phenotype. Here we present Power Window (PW), a sliding...
9.
Marchal A, Cirulli E, Neveux I, Bellos E, Thwaites R, Schiabor Barrett K, et al.
medRxiv
. 2024 Jan;
PMID: 38168184
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B*15:01 allele and asymptomatic...
10.
Bolze A, Cirulli E, Hajek C, Schnell Blitstein J, Grzymski J
JAMA Oncol
. 2023 Dec;
10(2):236-239.
PMID: 38153744
Importance: Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force...